Guardant Health Q2 Revenue Jumps 44%, Raises 2026 Guidance on Shield Momentum

summarizeSummary

Guardant Health reported Q2 2026 revenue of $335 million, up 44% year-over-year, and raised full-year revenue guidance to $1.34–$1.36 billion, driven by strong oncology and screening test volume growth.

check_boxKey Events · Earnings and Guidance · GH

• Q2 Revenue Surges 44%

  Total revenue reached $335.0 million, with oncology revenue up 38% to $219.1 million and screening revenue up over 250% to $52.9 million.

• 2026 Guidance Raised

  Full-year revenue guidance increased to $1.34–$1.36 billion (36–38% growth), up from $1.30–$1.32 billion, driven by higher Shield screening volume expectations of 270,000–285,000 tests.

• Shield Momentum Builds

  Shield screening test volume grew to approximately 66,000 in Q2, up from 16,000 a year ago, supported by inclusion in American Cancer Society guidelines and UnitedHealth Group coverage.

• Investment Spending Increases

  Non-GAAP operating expense guidance raised to $1.08–$1.10 billion and free cash flow burn now expected at $195–$205 million, reflecting accelerated investment in lab capacity.

auto_awesomeAnalysis · GH · Industrial Applications And Services

Guardant Health delivered a strong Q2 with revenue up 44% to $335 million, driven by a 63% surge in oncology test volume and a more than 250% jump in screening revenue. The company raised its full-year 2026 revenue guidance by $40 million at the midpoint, now expecting $1.34–$1.36 billion, reflecting accelerating Shield adoption and broad commercial momentum. However, operating expenses and cash burn guidance also increased as the company invests in capacity to support growth. With $1.2 billion in cash and a clear path to scale, the raised outlook signals confidence in sustained demand, though profitability remains a longer-term story.